Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

 Funding The Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study was supported by a research grant from Roche (Basel, Switzerland). The HBV99-01 study was organized and sponsored by the Foundation for Liver Research (SLO), Rotterdam, The Netherlands. Financial support and study medication for the HBV99-01 study was provided by Schering-Plough International (Kenilworth, NJ) and GlaxoSmithKline (Greenford, UK).

 Conflicts of interest These authors disclose the following: Erik H.C.J. Buster received speaker's honoraria from Novartis and Roche; George K. Lau consulted for Roche and Novartis; Teerha Piratvisuth consulted for GlaxoSmithKline, Novartis, and Schering-Plough, and received research support from Roche and Bristol-Myers Squibb; Stefan Zeuzem was a consultant for Bristol-Myers Squibb, Gilead, Novartis, Roche, and Schering-Plough, was on the speaker's bureau for Gilead and Novartis, and received research support from Roche; Harry L. A. Janssen received research support from Bristol-Myers Squibb, Gilead, Novartis, Roche, Schering-Plough, and was a consultant for Bristol-Myers Squibb, Novartis, and Roche. The remaining authors disclose no conflicts. Potential investigator conflicts of interest have not been disclosed to study participants.

PII: S0016-5085(09)01551-0

doi: 10.1053/j.gastro.2009.08.061

© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.